In this roundup, we provide a summary of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...

This week's clinical update features news from Editas Medicine, which recently announced that the U.S. Food and Drug Administration (FDA) has granted...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

This week’s clinical update looks at a Phase 1 trial for ET-01, a CRISPR-edited blood cell therapy for beta thalassemia.

Results from the first clinical trials using CRISPR in persons have been reported. The early first attempts showed safety and feasibility but did not...

New data confirms CRISPR gene editing as a cure for sickle cell disease and β-thalassemia, though it's too soon for firm conclusions on long-term...